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Abstract
Background Osseointegrated percutaneous implants pro-
vide direct anchorage of the limb prosthesis to the residual
limb. These implants have been used for the rehabilitation
of transhumeral amputees in Sweden since 1995 using a
two-stage surgical approach with a 6-month interval
between the stages, but results on implant survival, adverse
events, and radiologic signs of osseointegration and adap-
tive bone remodeling in transhumeral amputees treated
with this method are still lacking.
Questions/purposes This study reports on 2- and 5-year
implant survival, adverse events, and radiologic signs of
osseointegration and bone remodeling in transhumeral
amputees treated with osseointegrated prostheses.
Methods Between 1995 and 2010, we performed 18 pri-
mary osseointegrated percutaneous implants and two
implant revisions in 18 transhumeral amputees; of those, 16
patients were available for followup at a minimum of 2
years (median, 8 years; range, 2–19 years). These include
all transhumeral amputees who have received osseointe-
grated prostheses and represented approximately 20% of
the all transhumeral amputees we evaluated for potential
osseointegration during that time; general indications for
this approach included transhumeral amputation resulting
from trauma or tumor, inability to wear or severe problems
wearing a conventional socket prosthesis, eg, very short
residual limb, and compliant patients. Medical charts and
plain radiographs were retrospectively evaluated.
Results The 2- and 5-year implant survival rates were
83% and 80%, respectively. Two primary and one revised
implant failed and were removed because of early loos-
ening. A fourth implant was partially removed because of
ipsilateral shoulder osteoarthritis and subsequent arthro-
desis. The most common adverse event was superficial
infection of the skin penetration site (15 infections in five
patients) followed by skin reactions of the skin penetration
site (eight), incomplete fracture at the first surgery (eight),
defective bony canal at the second surgery (three), avas-
cular skin flap necrosis (three), and one deep implant
infection. The most common radiologic finding was prox-
imal trabecular buttressing (10 of 20 implants) followed by
endosteal bone resorption and cancellization (seven of 20),
cortical thinning (five of 20), and distal bone resorption
(three of 20).
Conclusions The implant system presented a survivorship
of 83% at 5 years and a 38% 5-year incidence of infectious
complications related to the skin penetration site that were
easily managed with nonoperative treatment, which make
it a potentially attractive alternative to conventional socket
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arm prostheses. Osseointegrated arm prostheses have so far
only been used in transhumeral amputations resulting from
either trauma or tumor. Their use has not been tested and is
therefore not recommended in transhumeral amputations
resulting from vascular disease. This method could theo-
retically be superior to socket prostheses, especially in
transhumeral amputees with very short residual humerus in
which the suspension of a conventional prosthesis is dif-
ficult. Comparative studies are needed to support its
potential superiority. Moreover, the radiological findings in
this study need to be followed over time because some of
them are of uncertain long-term clinical relevance.
Level of Evidence Level IV, case series. See Guidelines
for Authors for a complete description of levels of
evidence.
Introduction
It has been 19 years since the principle of osseointegration
was implemented for the rehabilitation of transhumeral
amputees in Sweden. This method allows direct anchorage
of the prosthetic limb to the humeral bone using a threaded
titanium implant (fixture), which is surgically attached into
the residual bone at a first operation (S1) [4]. At a second
operation (S2), a titanium extension (abutment) is inserted
into the fixture and secured with an abutment screw
(Fig. 1). The abutment penetrates the skin and serves as the
anchoring point for the attachment of the prosthetic limb.
The idea of a bone-anchored implant penetrating the
skin and coming in direct contact with the outer environ-
ment is challenging and often met with skepticism because
the outer part of such an implant is inevitably contaminated
by the skin flora and is expected to become infected and
progress to deep infection and therefore fail. However,
despite frequent colonization of the skin penetration site by
potentially virulent bacteria, only few infections leading to
implant removal have occurred [6]. The Osseointegrated
Prostheses for the Rehabilitation of Amputees (OPRA;
Integrum AB, Mo¨lndal, Sweden) implant system has been
used in transfemoral amputees for more than 20 years with
recently reported cumulative success rate at 2-year fol-
lowup of 92% in a prospective study in 51 patients [2].
These amputees have increased ROM in the hip and better
sitting comfort compared to socket prostheses [3]. Radio-
stereometric analysis in transfemoral amputees indicated
stable fixation of the implant and periprosthetic bone
remodeling similar to that seen around uncemented hip
stems [5]. The radiologic changes were consistent with
stress shielding and included endosteal and distal bone
resorption, cortical thinning, cancellization, and proximal
trabecular buttressing (Table 1). In short-term studies, this
periprosthetic bone remodeling has not compromised the
stability of the implant in transfemoral amputees but its
long-term clinical relevance is still unknown. Although the
biomechanics differ between a residual femur and a
residual humerus, similar findings should be expected in
the radiographs of transhumeral amputees. However, to our
knowledge, there still are no published data on implant
survival, adverse events and radiologic signs of osseoin-
tegration, and adaptive bone remodeling in transhumeral
amputees treated with this method.
We therefore sought to evaluate 2- and 5-year implant
survival, adverse events, and radiologic signs of osseoin-
tegration and bone remodeling in transhumeral amputees
treated with osseointegrated prostheses.
Patients and Methods
The study was conducted as a retrospective case series.
Between 1995 and 2010, we performed 18 primary os-
seointegrated percutaneous implants in 18 transhumeral
amputees; of those, two patients underwent implant revi-
sion as a result of early (\ 2 years) fixture loosening and
one patient had his abutment permanently removed as a
result of shoulder osteoarthritis and subsequent shoulder
arthrodesis. Of the initial number of transhumeral ampu-
tees, 16 patients were available for followup at a minimum
of 2 years and 13 patients at 5 years (median, 8 years;
range, 2–19 years). This group includes all transhumeral
amputees who have received osseointegrated prostheses in
our center and represents approximately 20% of the all
transhumeral amputees we evaluated for potential osseo-
integration during that time; general indications for this
approach included transhumeral amputation resulting from
trauma or tumor, inability to wear or severe problems
wearing a conventional socket prosthesis, eg, very short
residual limb, and compliant patients.
The mean patient age at implantation was 42 years (range,
19–69 years); two were women and 16 men. The cause of
Fig. 1 The percutaneous implant that was used in our study consists
of three parts: the fixture, the abutment, and the abutment screw.
Reproduced with permission and copyright  of the British Editorial
Society of Bone and Joint Surgery [2].
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amputation was either trauma (16) or malignant tumor (two)
and the mean time interval from amputation to S1 was 9 years
(range, 1.5–33 years). The study has been approved by the
Swedish Regional Ethics Committee in Gothenburg.
Transhumeral amputees referred to the Center of
Orthopaedic Osseointegration in Gothenburg were assessed
by a team consisting of an orthopaedic surgeon, an occu-
pational therapist, a prosthetist, and a coordinator. Those
who were eligible for osseointegration (approximately 20%
of all transhumeral amputees) were scheduled for surgery.
Briefly, the surgical technique at S1 consisted of reaming
and tapping of the medullary cavity and insertion of the
fixture, which was countersunk by 2 cm (Fig. 2). The
residual space distally to the fixture was packed with
autologous bone graft to keep the fixture away from the
future skin penetration site and to create a bone stock that
would prevent distal bone resorption from exposing the
fixture and increase the contact area between bone and skin
at S2. The wound was then closed. Postoperatively the
patients were allowed to wear their socket prosthesis and
after 4 to 6 months, they underwent S2. At S2 the distal
bone was drilled and the abutment was inserted. All mus-
cles were shortened and firmly attached to the periosteum
of the humerus. A skin flap was raised and the skin pene-
tration site was created and firmly attached to the distal end
of the humerus. Six weeks after S2, a short training pros-
thesis was attached to the abutment and rehabilitation was
started by successively increasing loading until they were
able to wear a long prosthesis [4]. The followup protocol
included clinical examination by an orthopaedic surgeon
and an occupational therapist at the outpatient clinic with
plain radiographic examination after S1 and S2 and 6
months and 1, 2, 3, 5, 7, 10, 13, and 15 years after S2.
Table 1. Definitions, adverse events and their severity, and radio-
logic changes
Adverse event Definition
Superficial infection of the
skin penetration site
Clinical signs of infection (redness,
swelling, purulent discharge with
positive bacterial cultures from the
skin/abutment interface)
necessitating the use of local, oral,
and/or IV antibiotics
Skin reactions at the skin
penetration site
Color change such as purpleness or
redness, serous discharge, or the
presence of a granulation ring; the
latter is a ring of granulation tissue
covered by epithelium that surrounds
the abutment (Fig. 3)
Deep implant infection Infection in the intramedullary canal
proximally to the fixture, presenting
with pain and swelling of the residual
arm as well as positive
intramedullary bacterial cultures
Incomplete distal fracture at
S1 surgery
Incomplete fracture or erosion of the
distal cortical bone while reaming or
introducing the fixture in the form of
a spiral fracture or a partial bone
defect that does not compromise the
fixture’s primary stability
Defect of the bony canal at
S2 surgery
Limited loss of the wall of the bony
canal, which occurs during drilling
for the introduction of the abutment
at S2 surgery
Partial skin flap necrosis Insufficient viability of the skin at the
skin penetration site during the first
weeks after S2 surgery
Severity of adverse event Definition
Mild Easily tolerated by the by the amputee
Moderate Causes sufficient discomfort to interfere
with daily activities
Severe Causes hospitalization and/or surgery
Radiologic changes Definition
Endosteal bone resorption Resorption of endosteal bone around the
threads of the fixture (Zones 1–12;
Fig. 4)
Distal bone resorption Resorption of the distal bone causing
exposure of the fixture (Zones A, B,
C, and D; Fig. 4)
Cancellization Increase in the porosity of the cortex
surrounding the fixture
Cortical thinning Decrease of the width of the cortex
around the fixture
Proximal trabecular
buttressing
Increase in the density of the cortical
and/or trabecular bone at the
proximal end of the fixture
S1 = first surgery; S2 = second surgery; IV = intravenous.
Fig. 2 Direct postoperative radiograph is shown after S1. The fixture
is countersunk by 2 cm into the medullary cavity and the residual
space at its distal end is filled by autologous bone graft, which is held
under compression by the so-called ‘‘graft screw.’’ At S2, the graft
screw is removed and the healed bone graft is drilled to a diameter
equal to the diameter of the abutment.
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The cumulative implant survival at each followup was
measured as the number of implants that had not failed
divided by the number of implants that could have failed
since S1 (Table 2). Removal of the fixture or permanent
removal of any implant component for any reason was
considered as the endpoint for implant failure. For the
study of adverse events and radiologic signs of bone
remodeling, the medical charts and plain radiographs were
examined by one observer (GT). The adverse events were
divided into six categories according to the type of event:
superficial infections of the skin penetration site, deep
infections, skin reactions of the skin penetration site
(Fig. 3), incomplete distal fractures at S1, defect of the
bony canal at S2, and avascular skin flap necrosis
(Table 1). Moreover, they were categorized according to
their severity into mild, moderate, and severe (Table 1).
The 2- and 5-year incidence was calculated for each
adverse event where applicable. The plain radiographs
included an AP and a lateral view of the residual arm
perpendicular to the fixture. The bone around the fixture
was divided into six zones and the distal bone into two
zones on each view as previously done in transfemoral
amputees with osseointegrated prostheses [5] (Fig. 4). The
radiographs were examined for signs of endosteal bone
resorption (Fig. 5), cancellization (Fig. 6), and cortical
thinning (Fig. 7). The bone proximal to the fixture was
examined for signs of trabecular buttressing (Fig. 5) and
around the abutment for signs of distal bone resorption
(Fig. 7). The same terminology and definitions were used
as in transfemoral amputees for the results to be compa-
rable (Table 1). The postoperative radiographs after S2
were used as a reference and were compared to the
radiographs at each followup. The assessment of the
radiographs was qualitative and each zone was either
positive or negative for the mentioned radiological
changes. This part of the study included both primary and
revised implants (total of 20). In two patients the postop-
erative S2 radiographs were missing and the 6-month
postoperative radiographs were used as a reference instead.
Apart from these two radiographs, 10 more radiographs
were missing. Those radiographs were counted as un-
changed in relation to the previous radiographs.
Results
Implant Survival
The implant’s cumulative survival rate at 2 and 5 years (post-
S1) was 83% and 80%, respectively (Table 2). Three
patients had implant failure. In two patients the fixture failed
as a result of loosening within 2 years from S1. Both patients
underwent two-stage revision surgery. Intraoperative cul-
tures were positive for Staphylococcus aureus and
coagulase-negative staphylococci. After implant removal,
the patients received antibiotics (clindamycin and rifampi-
cin) and negative intramedullary cultures were secured
before reimplantation. One of the two patients had a second
fixture loosening; this patient underwent fixture removal and
closure of the skin penetration site and is now not using any
kind of prosthesis because the patient was already unsatisfied
with socket prostheses before undergoing osseointegration.
Intraoperative cultures at fixture removal were negative. The
other patient has a well-fixed revised fixture up to date (6
years). In these two patients, the primary stability of the
fixture at the first S1 was reported by the surgeon as unsat-
isfactory, meaning that the torque would not increase while
installing the fixture deeper. All three fixture loosenings
occurred within 2 years after implantation. There were no
clinical signs of infection and the only symptom was pain at
loading. The radiographs were unchanged since S1. No late
fixture loosening has been observed. A third patient devel-
oped glenohumeral osteoarthritis in the ipsilateral shoulder
and underwent shoulder arthrodesis. He was unable to wear
any kind of prosthesis because of persistent shoulder pain
and was treated with permanent removal of the abutment and
closure of the skin penetration site leaving the osseointe-
grated fixture in the humerus. Although the reason for failure
was not related to the implant, this implant was counted as
failed because it could no longer serve as an anchoring point
for prosthesis.
Table 2. Implant survival at each followup
Followup (years) Implants at
risk for failure
since the first
surgery (could
have failed)
Implants
that have
not failed
since the
first
surgery
Implants
that have
failed
since the
first
surgery
Survival
(%)
0 (Stage 1) 18 18 0 100
0.5 (Stage 2) 18 18 0 100
1 18 16 2 89
2 18 15 3 83*
3 17 14 3 82
5 15 12 3 80*
7 11 8 3
10 8 5 3
13 6 3 3
15 4 1 3
* Note that the survival rate appears to drop between 2- and 5-year
followup despite that no new implant failure has occurred during that
time interval because there were three less implants available at 5
years than at 2 years.
2950 Tsikandylakis et al. Clinical Orthopaedics and Related Research1
123
Adverse Events
A total of 43 adverse events were recorded. Twenty-one
(49%) were mild, 16 (37%) moderate, and six (14%)
severe. Superficial infections of the skin penetration site
accounted for 35% (15 infections) of all adverse events and
were encountered in five patients. Their 2- and 5-year
incidence was 19% (three of 16) and 38% (five of 13),
respectively. Their treatment included surgical revision of
the skin penetration site, local mechanical cleaning, local
or oral antibiotics, and restriction of soft tissue mobility by
using a silicone liner (Table 3). The duration of antibiotic
treatment varied from 2 to 6 weeks. Although recurrences
were common, in three of five patients, the infections
healed uneventfully. In the remaining two patients, the
infections healed but they developed increased soft tissue
mobility at the skin penetration site. All five patients are
still able to use their prosthesis. The most common path-
ogen was S aureus (three of five). Deep implant infection
occurred in one patient 31
.
2 years after S1 and without any
Fig. 3A–C Skin reactions of the skin penetration site are shown.
Changes in the skin color included purpleness (A) or redness (B). The
skin around the abutment is elevated by underlying hypertrophic
granulation tissue forming the ‘‘granulation ring’’ (C, arrows);
purpleness and some serous secretion are also evident (C).
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history of superficial infection. It presented with mild signs
of infection such as pain and tenderness in the residual arm,
limited redness and discrete discharge from the skin pen-
etration site, and periosteal reaction on the radiographs.
Histology was consistent with osteomyelitis and cultures
were positive for Escherichia coli. The patient was treated
with oral antibiotics for 3 months, which resulted in
complete regression of the infection and the patient being
able to use the prosthetic arm again.
Skin reactions of the skin penetration site accounted for
19% of all adverse events and were noticed in eight
patients. Their 2- and 5-year incidence was 38% (six of 16)
and 62% (eight of 13), respectively. They were treated with
clinical observation alone or local nonsurgical cleaning and
chemical cauterization (AgNO3) and all but one resolved
allowing the patients to use their prostheses (Table 4).
Incomplete distal fracture of the residual bone at S1
accounted for 19% (eight fractures) of all adverse events
and occurred in 44% (eight of 18) of S1 performed. In six
fractures, no special treatment was conducted. One fracture
was treated with autologous bone transplantation and
another one with only modified passive rehabilitation
between S1 and S2. All fractures were not evident on the
Fig. 4A–B These AP (A) and lateral (B) views show the 12 zones
(1–12) around the fixture and the four zones at the distal bone (A–D)
as well as the bone proximally to the fixture (PB).
Fig. 5A–B This 5-year postoperative radiograph (B) shows a well-
fixed fixture with signs of endosteal bone resorption (lower arrow)
and proximal trabecular buttressing (upper arrow). Comparison is
made to the S2 postoperative radiograph (A).
Fig. 6A–B A postoperative radiograph at S2 is shown (A). Fifteen
years later, cancellization is evident (B). This was one of the first
patients who received an osseointegrated arm prosthesis. The fixture
was custom-made and the technique of countersinking the fixture by 2
cm in the medullary cavity was not yet developed. This is why the
distal bone looks as if it has already been resorbed at S2 (A).
Fig. 7A–B This radiograph at 3-year followup (B) shows signs of
cortical thinning in the distal third of the fixture (upper arrow) and
distal bone resorption at the bone canal distally to the fixture (lower
arrow). Some proximal buttressing is also evident at the proximal
third of the fixture. Comparison is made to the S2 postoperative
radiograph (A).
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radiographs 6 months postoperatively and S2 was per-
formed as scheduled. However, one implant failed 2 years
postoperatively. No periprosthetic fracture after S1 has
occurred up to date. Adverse events at S2 included a lim-
ited defect of the bony canal (three) that occurred while
drilling for the abutment and partial skin flap necrosis
(three). Bone defects healed uneventfully and partial skin
flap necroses healed within 2 to 4 weeks after skin de´bri-
dement and treatment with oral antibiotics.
Apart from the mentioned adverse events, three amputees
had phantom pain in their arm. In one of those, a neuroma
was identified and removed during S2 leading to pain relief,
whereas in the remaining two, the pain was persistent despite
treatment with amitriptyline and gabapentine. A fourth
amputee sustained a collum chirurgicum fracture after fall-
ing, which healed with nonsurgical treatment.
Radiologic Findings
The most common radiologic finding was proximal trabec-
ular buttressing (10 of 20 implants) followed by endosteal
bone resorption and cancellization (seven of 20), cortical
thinning (five of 20), and distal bone resorption (three of 20).
Proximal buttressing became more common with time with
its frequency increasing from five of 16 implants at 2 years to
six of 13 implants at 5 years. Cancellization had also an
increasing trend from three of 16 to three of 13. Cortical
thinning had a low frequency at 2 and 5 years (four of 16 and
two of 13, respectively) and endosteal bone resorption was
observed in up to three implants at each followup. Distal
bone resorption was observed once at 2 years and twice at 5
years. Moreover, it was limited and never exposed the thread
of the fixture. Cancellization was distributed quite evenly
among the zones around the fixture showing a slight pref-
erence for its middle third, whereas near bone resorption and
cortical thinning were evident mostly around its distal third
(Fig. 8).
Discussion
The implementation of osseointegration for the rehabilita-
tion of amputees challenges the basic principle of implant
surgery stating that implants must be sufficiently covered
by soft tissues to avoid infection. Although there is [ 20
years of experience of percutaneous bone-anchored
implants in transfemoral amputees [2], this method is still
met with skepticism in the orthopaedic community. This
report is the first of which we are aware on infectious and
other adverse events in transhumeral amputees; we also
Table 3. Superficial infections at the skin penetration site: number of relapses, treatment, and clinical outcome
Patient
number
Time of first
infection*
(months)
Number
of
relapses
Number of
relapses per
year
Treatment Outcome
1 4 6 2 3 surgical de´bridements of the
SPS + 1 surgical revision
of the SPS + antibiotics
Partial loss of skin attachment at SPS.
Uses prosthesis
2 14 3 0.85 Antibiotics Free of infection for 3 years
3 38 1 1 Antibiotics Free of infection for 9 years
4 5 0 Surgical irrigation of the SPS +
antibiotics
Increased mobility of soft tissues around
the SPS; intermittent discharge; uses
prosthesis
5 38 0 Antibiotics Free of infection for 6 years
* Since second surgery; SPS = skin penetration site.
Table 4. Skin reactions of the skin penetration site: treatment and
clinical outcome
Patient
number
Time of first
skin reaction*
(months)
Treatment Outcome
1 60 Observation Resolved
2 7 Observation Persistent secretion,
limited prosthetic
use
3 50 Cauterization
(AgNO3)
Resolved
4 16 Soft tissue
supporting pad
Resolved
5 3.5 Cauterization Resolved
6 6 Local
nonsurgical
cleaning
Resolved
7 12 Local
nonsurgical
cleaning
Resolved
8 17 Observation Resolved
* Since second surgery.
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sought to provide data on the 2- and 5-year implant sur-
vival and to comment on osseointegration and adaptive
bone remodeling around these implants.
This study has certain limitations. The number of patients
(18) is low and the study was retrospective. The patient
cohort was selected by a multidisciplinary team (orthopaedic
surgeon, occupational therapist, prosthetist, coordinator)
based on the patient’s reason for amputation (trauma or
tumor), wish for better function, and estimated compliance
without randomization and represents approximately 20% of
all transhumeral amputees that are referred to our center.
Therefore, highly motivated patients with good compliance
were more likely to be selected for osseointegration. How-
ever, the observer (GT) who reviewed the medical charts and
plain radiographs was not part of this multidisciplinary team
or active in the treatment and followup of the amputees.
Moreover, no comparison was made between the osseoin-
tegration cohort and amputees with socket arm prostheses;
also, the study did not include any patient-reported outcomes
for pain, function, and prosthetic use, which makes it difficult
to make any conclusions about the superiority of one or the
other method. In some instances, the patients missed their
followup appointment resulting in potential adverse events
being registered at the next followup. In these instances the
exact time when the adverse event had occurred was not
registered in the medical charts. Because a part of the implant
is in direct contact with the outer environment and therefore
contaminated by bacteria, it is difficult to draw a distinct line
between skin reactions as a result of inflammation of the soft
tissues of the skin penetration site and manifest bacterial
superficial infections. Clinical signs of inflammation, posi-
tive bacterial cultures, and antibiotic treatment given were
used as criteria for infection trying to distinguish infection
from inflammation. Bacterial contamination has however
previously been found in half of asymptomatic patients with
an osseointegrated percutaneous implant [6]. Bacteria may
be commensals, mutualistic, or pathogenic and potential
‘‘pathogens’’ may or may not actually produce infection.
Presumably some inflammatory skin reactions have been
registered as superficial infections and vice versa. All
radiographs were not available for examination and more-
over the assessment of radiologic changes was made by one
observer (GT) without calculating intraobserver error.
This implant system had a 2- and 5-year survival rate of
83% and 80%, respectively, in transhumeral amputees,
which appears lower than the 2-year survival rate (92%) of
the same implant system in transfemoral amputees in the
OPRA study [2]. We believe that this difference can be
explained by the higher experience of our center in
transfemoral amputees and that the use of custom-designed
components can increase the risk of not having optimal
primary stability at implant insertion. In contrast to endo-
prostheses such as hip and knee prostheses, aseptic loosening
cannot practically be diagnosed because the system is open
to the outer environment and any failed osseiontegration
inevitably leads to contamination of the bone-fixture inter-
face. The importance of good primary stability of the fixture
at S1 is highlighted because poor primary stability could
compromise osseointegration and was reported in two
implant failures. No mechanical problems of the implant
systems occurred, in contrast to transfemoral amputees in
whom bending or fracture of the abutment or the abutment
screw has been reported [2].
Superficial infections of the skin penetration site were the
most common adverse event in transhumeral amputees. At 2
years, three of 16 (19%) and at 5 years five of 13 (38%)
patients had developed at least one superficial infection.
Transfemoral amputees had a frequency of infection of 58%
(28 of 48 patients at 2 years), which might be the result of less
mobility of the soft tissues in transhumeral amputees [2].
Nonsurgical treatment or minor skin revisions was sufficient
in all superficial infections, but the treatment needs to be
standardized. None of the superficial infections progressed
to a deep implant infection or caused implant revision during
the study period. The only deep implant infection occurred
late (3.5 years after S1) in contrast to transfemoral amputees
Fig. 8 This chart shows the
distribution of endosteal bone
resorption, cortical thinning,
and cancellization in the 12
zones around the fixture. End-
osteal bone resorption and
cortical thinning were observed
mainly in the distal third of the
bone-fixture interface (Zones 3,
4, 9, and 10), whereas cancelli-
zation was observed mainly in
its middle third (Zones 2, 5, 8,
and 11).
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in whom deep infections were reported early in the postop-
erative period [2]. Skin reactions represent an inflammatory
status of the skin penetration site that may or may not lead to
a superficial infection. In our study, only three of eight
patients with skin reactions of the skin penetration site
developed a superficial infection after 8 to 30 months,
indicating that skin reactions alone are not a sufficient factor
for the development of superficial infections. A classifica-
tion system of the skin reactions of the skin penetration site
with a predictive value for the risk of development of
superficial infections would be useful. Skin motion around
the abutment is believed to be a predisposing factor for
superficial infections and/or skin reactions of the skin pen-
etration site. Our method is based on firmly attaching the
skin onto the distal bone at S2 to minimize the risk for such
adverse events. On the other hand, superficial infections,
especially combined with distal bone resorption, could lead
to loss of skin attachment and therefore increase the risk for
new superficial infections of the skin penetration site. In our
series loss of skin attachment was partial and occurred in one
patient at 15-year followup after six relapses of superficial
infections of the skin penetration site (Table 3). In this ret-
rospective study, details of attachment of the skin
penetration site were not possible to evaluate thoroughly.
We hypothesize that a well-attached skin penetration site
will lead to less draining and infectious complications but
further studies are needed to explore this. Skin reactions and
superficial infections of the skin penetration area were
common but were not severe and were easily managed.
These complications should be weighed against the common
complaints of transhumeral amputees using a socket pros-
thesis, which include restricted shoulder ROM and
discomfort because of warmth and excessive perspiration
caused by the socket and the heavy harness. Prosthetic
rejection has been reported between 23% and 26% [1] in this
group, whereas in our cohort, 16 of 18 patients still use their
osseointegrated prosthesis. The absence of a socket and
harness in patients with osseointegrated arm prostheses
should eliminate these problems reported by almost all
conventional socket arm prosthesis users.
The residual bone around the implant in transhumeral
amputees showed radiologic changes similar to those in
transfemoral amputees although with some differences.
Distal bone resorption in the humerus occurred to a much
lesser extent than in the femur and did not result in exposure
of the fixture. Proximal buttressing, which was the most
common radiologic change in the humerus, also appeared
differently and looked rather like uniform thickening of the
bone at the proximal third and above the fixture than trian-
gular areas as observed in the transfemoral amputees [5].
This may be the result of the different forces that act on these
areas, because the residual femur is exposed for mainly
compressive forces and bending moments (walking),
whereas the residual humerus is exposed for mainly tensile
forces and bending moments (lifting). The latter put more
loading on the distal bone and less on the proximal bone in
transhumeral amputees compared with transfemoral.
Although the presence of proximal buttressing and distal
bone resorption can be explained by Wolff’s law as bone
remodeling consistent with stress shielding, the clinical
relevance of cancellization and cortical thinning is uncertain
because long-term studies are not available. They could
theoretically represent risk factors for periprosthetic fracture
in years to come. Endosteal bone resorption is also a
potential threat that could compromise the stability of the
fixture if extending more proximally than the distal third of
the fixture where it has so far been observed. Bone remod-
eling at the bone-fixture interface has so far not affected the
osseointegration of the fixture because no late loosening or
periprosthetic fracture has been reported.
To our knowledge, this is the first study on implant sur-
vival, adverse events, and radiologic signs of bone
remodeling in transhumeral amputees treated with an os-
seointegrated percutaneous implant, reporting up to 19 years
followup. We found an implant survivorship of 83% at 2
years and 80% at 5 years. The frequency of skin reactions and
infectious complications related to the skin penetration site
was relatively high (38% at 5 years), although most of them
were not serious and were easily managed with nonoperative
treatment. We also found a number of radiological changes
that need to be followed over time because some of them
have uncertain clinical relevance. Even so, we believe os-
seointegrated arm prostheses are a potentially attractive
alternative to conventional socket prosthesis that should be
considered, especially in very high transhumeral amputa-
tions in which adequate suspension of a socket prosthesis is
difficult. Osseointegrated arm prostheses have so far only
been used in amputations resulting from either trauma or
tumor. It is uncertain whether the implant has a similar sur-
vivorship in amputations resulting from vascular disease.
Our approach could theoretically provide transhumeral
amputees with better comfort and a greater shoulder ROM
than socket prostheses. Comparative studies are needed to
support its potential superiority.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution, and reproduction in any medium, provided the original
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